• ESMO GI 2019: targeted therapy combination improves survival in colorectal cancer
    ESMO GI 2019: targeted therapy combination improves survival in colorectal cancer

    Data from the phase 3 BEACON CRC study presented at the ESMO World Congress on Gastrointestinal Cancer 2019.

  • ESMO GI 2019: colon cancer survival in patients with obesity and hyperglycaemia
    ESMO GI 2019: colon cancer survival in patients with obesity and hyperglycaemia

    New findings presented at the recent ESMO World Congress on Gastrointestinal Cancer 2019.

  • ESMO GI 2019: efficacy of flexible regorafenib dosing to relieve side effects
    ESMO GI 2019: efficacy of flexible regorafenib dosing to relieve side effects

    Results of the phase 2 REARRANGE study presented at the ESMO World Congress on Gastrointestinal Cancer 2019.

  • CRC: low-dose leucovorin offers similar response, survival in meta-analysis

    The shortage in 2008 prompted a switch to lower doses.

  • Bevacizumab biosimilar gets FDA nod for 5 cancer types

    Bevacizumab-bvzr could offer a cheaper alternative to the reference product.

  • Colon cancer: study identifies predictors of early death
    Colon cancer: study identifies predictors of early death

    Patients with social isolation warrant special attention.

  • Colorectal cancer: gradual dose escalation improves regorafenib safety

    An alternative approach for dose optimization.

  • Seafood intake is tied to lower colorectal cancer risk

    Large European study lends evidence to omega-3 fatty acids as mediators.

  • Deep sedation does not improve colonoscopy detection rate

    No advantage over moderate sedation for average-risk patients.

  • Yogurt may reduce colon cancer risk in men

    Data show lower risk for adenomas with high malignant potential.

  • Cancer risk in women who were breastfed as infants

    Results from a large prospective study of 548,741 women in the UK.

  • In FIT screens, one sample is enough

    2-sample tests were thought to offer greater sensitivity with intermittent bleeding.

  • CRC: Lynch syndrome screening not warranted after age 80 years

    Incremental diagnostic yield dropped substantially after age 70-75 years.

  • Colorectal cancer: managing secondary bowel obstruction

    An analysis of data from the Hospital Episode Statistics over a 10-year period

  • Load more